


## Pacritinib citrate

Cat. No.:	HY-16379B
CAS No.:	1228923-42-9
Molecular Formula:	C <sub>34</sub> H <sub>40</sub> N <sub>4</sub> O <sub>10</sub>
Molecular Weight:	664.7
Target:	JAK; FLT3
Pathway:	Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

#### Description

Pacritinib (SB1518) citrate is a potent inhibitor of both wild-type JAK2 (IC<sub>50</sub>=23 nM) and JAK2<sup>V617F</sup> mutant (IC<sub>50</sub>=19 nM). Pacritinib citrate also inhibits FLT3 (IC<sub>50</sub>=22 nM) and its mutant FLT3<sup>D835Y</sup> (IC<sub>50</sub>=6 nM). Pacritinib citrate can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF)<sup>[1][2][3]</sup>.

### CUSTOMER VALIDATION

- Nat Med. 2017 Nov;23(11):1319-1330.
- Science. 2017 Dec 1;358(6367):eaan4368.
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- Nat Commun. 2021 Aug 13;12(1):4917.
- Nat Commun. 2021 Jul 21;12(1):4441.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

- [1]. Hart S, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. *Leukemia*. 2011 Nov;25(11):1751-9.
- [2]. Hart S, et al. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. *Blood Cancer J*. 2011 Nov;1(11):e44.
- [3]. Komrokji RS, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. *Blood*. 2015 Apr 23;125(17):2649-55.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA